Video

Summary/Abstract

Deborah Mash, PhD, discusses the therapeutic potential of ibogaine, particularly in opioid use disorder.

Content

Deborah Carmen Mash is an American professor of neurology and of molecular and cellular pharmacology at the Leonard M. Miller School of Medicine, and director of the Brain Endowment Bank at the University of Miami.^[2][1] She is also the Chief Executive Officer and founder of DemeRx.^[3]

Early research[edit]

Mash became fascinated with the human brain while she was an undergraduate student at Florida State University.^[1] After completing a Bachelor of Arts degree there, she completed a Ph.D. program at the Miller School of Medicine at the University of Miami, and did a postdoctoral fellowship at Harvard Medical School's Beth Israel Hospital in Boston, Massachusetts.^[2] In 1986 she joined the faculty of her alma mater, the University of Miami.^[2][4]

Ibogaine[edit]

In 1994, the Food and Drug Administration of the United States granted Mash an Investigational New Drug license, to permit her to research the addiction-stopping capabilities of ibogaine (an oneirogen that occurs in some plants).^[5][6] A lack of funding and other barriers prevented the research from proceeding.^[5][7] Mash and her colleagues had previously discovered that ibogaine is a prodrug that metabolizes into a psychoactive called 12-hydroxyibogamine (or, noribogaine).^[4] In the late 1990s she provided some assistance to Healing Transitions Institute for Addiction, a drug detoxification clinic in Cancún where physicians oversaw patients' ibogaine treatments.^[8]